Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Non-Current Debt (2016 - 2017)

Historic Non-Current Debt for Bone Biologics (BBLG) over the last 2 years, with Q3 2017 value amounting to $7.2 million.

  • Bone Biologics' Non-Current Debt rose 2076.47% to $7.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $7.2 million, marking a year-over-year increase of 2076.47%. This contributed to the annual value of $7.6 million for FY2016, which is N/A changed from last year.
  • According to the latest figures from Q3 2017, Bone Biologics' Non-Current Debt is $7.2 million, which was up 2076.47% from $6.9 million recorded in Q2 2017.
  • Bone Biologics' Non-Current Debt's 5-year high stood at $7.6 million during Q4 2016, with a 5-year trough of $6.0 million in Q3 2016.